Catalent Releases Optiform™ Compound Optimization Platform
(Research Triangle Park, N.C.) Catalent Pharma Solutions is pleased to announce that the Optiform™ compound optimization platform, a novel, solid-state and highly-automated analysis platform for salt, crystal-form, and co-crystal screening, developed and refined over the past ten years within GlaxoSmithKline (GSK) will now be broadly available to early development scientists for the first time. The technology has resulted in faster and more material-efficient development workflows, making it easier to bring new drugs to market faster. The Optiform™ compound optimization platform has been applied to more than 500 compounds, spanning from early stage lead compounds through launched products. GSK has entered into an agreement with Catalent to utilize the Optiform™ platform to support its internal screening activities. The deal between Catalent and GSK was brokered by SR One, GSK’s corporate venture fund. (more…)
